GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Appili Therapeutics Inc (OTCPK:APLIF) » Definitions » EV-to-FCF

Appili Therapeutics (Appili Therapeutics) EV-to-FCF : -3.84 (As of Jun. 05, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Appili Therapeutics EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Appili Therapeutics's Enterprise Value is $9.00 Mil. Appili Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.34 Mil. Therefore, Appili Therapeutics's EV-to-FCF for today is -3.84.

The historical rank and industry rank for Appili Therapeutics's EV-to-FCF or its related term are showing as below:

APLIF' s EV-to-FCF Range Over the Past 10 Years
Min: -14.47   Med: -3.51   Max: 2.65
Current: -3.7

During the past 6 years, the highest EV-to-FCF of Appili Therapeutics was 2.65. The lowest was -14.47. And the median was -3.51.

APLIF's EV-to-FCF is ranked worse than
100% of 379 companies
in the Biotechnology industry
Industry Median: 8.31 vs APLIF: -3.70

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-05), Appili Therapeutics's stock price is $0.0337. Appili Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.031. Therefore, Appili Therapeutics's PE Ratio for today is At Loss.


Appili Therapeutics EV-to-FCF Historical Data

The historical data trend for Appili Therapeutics's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Appili Therapeutics EV-to-FCF Chart

Appili Therapeutics Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EV-to-FCF
Get a 7-Day Free Trial - -5.17 -4.76 -0.36 -0.99

Appili Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.74 -0.99 -1.50 -3.28 -3.70

Competitive Comparison of Appili Therapeutics's EV-to-FCF

For the Biotechnology subindustry, Appili Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Appili Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Appili Therapeutics's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Appili Therapeutics's EV-to-FCF falls into.



Appili Therapeutics EV-to-FCF Calculation

Appili Therapeutics's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=9.001/-2.342
=-3.84

Appili Therapeutics's current Enterprise Value is $9.00 Mil.
Appili Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.34 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Appili Therapeutics  (OTCPK:APLIF) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Appili Therapeutics's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.0337/-0.031
=At Loss

Appili Therapeutics's share price for today is $0.0337.
Appili Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.031.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Appili Therapeutics EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Appili Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Appili Therapeutics (Appili Therapeutics) Business Description

Traded in Other Exchanges
Address
1344 Summer Street, Suite 21, Halifax, NS, CAN, B3H 0A8
Appili Therapeutics Inc is a biopharmaceutical company. The company is engaged in novel antibiotic and anti-infective therapies to help patients suffering from serious infections. Its anti-infective portfolio currently includes major programs namely ATI-2307, ATI-1701, ATI-1503, ATI-1501 and Favipiravir.

Appili Therapeutics (Appili Therapeutics) Headlines

From GuruFocus

Appili Therapeutics Announces Overnight Marketed Equity Offering

By Business Wire Business Wire 05-17-2022